Differences in Clinical and Imaging Features between Asymptomatic and Symptomatic COVID-19 Patients

Table 6

Imaging features of asymptomatic carriers and COVID-19 patients at the late improvement stage [n (%)].

CT features	Late improvement stage
	Asymptomatic (n = 12)	COVID-19 (n = 23)
Prevalent lesion distribution within lobes
Peripheral area	7(58.33)	5(21.73)	4.69	0.06
Central area	0	0	—	—
Both peripheral and central area	5(41.67)	18(78.26)	4.69	0.06
Density and interior features
Ground glass opacity	2(16.67)	5(21.74)	0.13	1.00
Consolidation	2(16.67)	0	4.07	0.11
Both ground glass opacity and consolidation	8(66.67)	18(78.26)	0.56	0.69
Intralobular septal thickening	2(16.67)	5(21.74)	0.13	1.00
Interlobular septal thickening	1(8.33)	8(34.78)	2.89	0.12
Other features
Pleural effusion	0	0	—	—
Enlarged mediastinal lymph nodes	0	0	—	—

Note. Asymptomatic, those who remained asymptomatic; COVID-19, symptomatic COVID-19 patients; CT, computed tomography; the fisher exact test was used.